These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib/II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen. Read more . . .
Adding cisplatin to the standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen).